Related Experiment Video

Updated: Aug 17, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Monoamine oxidase in schizophrenia: an overview

R J Wyatt, S G Potkin, T P Bridge

    Schizophrenia Bulletin
    |January 1, 1980
    PubMed

    Insights

    Studies show decreased monoamine oxidase (MAO) enzyme activity in the platelets of chronic schizophrenia patients compared to controls. This finding suggests a potential role for MAO in the etiology of some schizophrenia forms.

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Biochemistry

    Background:

    • Schizophrenia is a complex psychiatric disorder with multifactorial etiology.
    • Monoamine oxidase (MAO) is an enzyme involved in neurotransmitter metabolism.
    • Previous research has investigated the potential link between MAO and schizophrenia.

    Purpose of the Study:

    • To review existing studies on the role of monoamine oxidase (MAO) in schizophrenia.
    • To examine the significance of altered MAO enzyme activity in schizophrenia patients.

    Main Methods:

    • Literature review of studies measuring monoamine oxidase (MAO) activity.
    • Comparison of MAO enzyme activity in chronic schizophrenic patients versus control groups.
    • Analysis of challenges in comparing MAO activity across different patient populations.

    Main Results:

    • The majority of studies report decreased platelet monoamine oxidase (MAO) enzyme activity in chronic schizophrenic patients.
    • Variability in MAO activity measurements across different patient cohorts was observed.

    Conclusions:

    • Decreased platelet monoamine oxidase (MAO) activity is a consistent finding in chronic schizophrenia.
    • This reduction in MAO activity may play an etiological role in specific subtypes of schizophrenia.

    More Related Videos

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices07:56

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

    Published on: August 11, 2021

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra05:14

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

    Published on: September 8, 2021

    Related Concept Videos

    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Psychosis and Antipsychotic Drugs: Overview01:28

    Psychosis and Antipsychotic Drugs: Overview

    The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
    Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

    Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

    Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
    Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
    Mania and Antimanic Drugs: Overview01:24

    Mania and Antimanic Drugs: Overview

    Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
    Antidepressant Drugs: MAOIs and Other Agents01:23

    Antidepressant Drugs: MAOIs and Other Agents

    Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
    Biological Causes of Schizophrenia01:29

    Biological Causes of Schizophrenia

    Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
    Genetic Factors in Schizophrenia
    The genetic basis of schizophrenia is strongly supported by family and twin studies.